| Literature DB >> 34305583 |
Haocheng Xian1, Jiayi Li1, Yimeng Zhang1, Ditian Li1, Yinan Zhu1, Siyan Li1, Zhelun Tan1, Zhibin Lin1, Xuejun Li1, Yan Pan1.
Abstract
Ganoderma lucidum (Lingzhi) polysaccharide peptide (GL-pp) is a component of the globally acknowledged traditional Chinese medicine Ganoderma lucidum; Ganoderma lucidum is known for its sedative, hypnotic, immune regulatory, antitumor, and other pharmacological effects. In recent years, sleep disorders have been linked to many diseases and human body disorders, including cancer. Some experimental studies in mice found that sleep fragmentation could promote tumor development and progression. However, effects on GL-pp on tumor metastasis under circumstances of sleep disorders have rarely been studied. Thus, in this study, we used mice with sleep fragmentation (SF) bearing B16-F10-luc-G5 melanoma tumors to investigate the effect of SF on melanoma metastasis. Furthermore, we investigated the antitumor and antimetastatic effects of GL-pp (80 mg/kg) in mice suffering from SF and bearing B16-F10-luc-G5. Then, whole proteomics was used to analyze the differences in protein expression in the lung tissue between SF mice bearing B16-F10-luc-G5 with and without GL-pp administration. High-throughput pyrosequencing of 16S rRNA was also used to analyze the impact of GL-pp on the gut microbiota composition in SF mice bearing B16-F10-luc-G5. Last, the effects of GL-pp on macrophage polarization and TNF-α serum levels were detected. Collectively, we found that SF significantly facilitated the B16-F10-luc-G5 melanoma tumor metastasis in mice, while GL-pp significantly reduced B16-F10-luc-G5 melanoma tumor metastasis under the condition of SF, in which proteomics and gut microbiota had been changed greatly.Entities:
Keywords: Ganoderma lucidum polysaccharide peptide; gut microbiota; proteomics; sleep fragmentation; tumor metastasis
Year: 2021 PMID: 34305583 PMCID: PMC8296642 DOI: 10.3389/fphar.2021.650216
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1The flowchart of animal treatments.
FIGURE 2The flowchart of quantitative proteomic analysis.
FIGURE 3Inhibitory effects of GL-pp on tumor metastasis in mice with B16-F10-luc-G5 and SF. To show relative changes of tumor lung metastasis over time, luminescent intensity images were processed using living image in vivo. There were three groups, including tumor group with the burden of B16-F10-luc-G5 cells (Tumor group), T + SF group with SF and the burden of B16-F10-luc-G5 cells (T + SF group), and GL-pp group with SF, tumor cells burden, and the administration of 80 mg/kg GL-pp (GL-pp group). (A) The body weight of mice was observed over time. (B) The quantification of pulmonary luminescent intensity was recorded with living image in vivo. (C) Lung metastasis luminescent intensity images of a representative mouse from each group are shown. (D) Delegated mice pulmonary tissue with B16-F10-luc-G5 tumor foci of each group is shown. (E) The number of lung metastatic foci was counted. (F) H&E staining of pulmonary tissue sections (×100). (G) Percentage of alveolar area was calculated. The results are shown as mean ± SD, n = 5. ## p < 0.01 compared with the Tumor group; △△ p < 0.01 compared with the T + SF group.
FIGURE 4Quantitative protein expression profiling and the global signal transduction network of the significantly altered genes between the T + SF group and the GL-pp group. (A) Heat map of 227 significantly differentially expressed proteins between the T + SF group and the GL-pp group with the gene names listed on the right (orange indicates a higher expression level, and blue indicates a lower expression level, p < 0.05). (B) The global signal transduction network, the nodes in which were connected when their corresponding encoded gene products were connected directly or indirectly by a linker gene in the interaction network, and the size of each node indicates the degree of the gene. Red indicates upregulated and blue means downregulated key regulatory genes.
Forty-three key regulatory genes identified from the global signal transduction network between the T + SF group and the GL-pp group.
| protein | Gene symbol | Description | Style | Degree |
|---|---|---|---|---|
| LAMA2 |
| Laminin, alpha 2 | Up | 55 |
| VWF | Vwf | von Willebrand factor homolog | Up | 51 |
| FAK1 | Ptk2 | PTK2 protein tyrosine kinase 2 | Up | 43 |
| YAP1 | Yap1 | Yes-associated protein 1 | Up | 35 |
| AL3A1 | Aldh3a1 | Aldehyde dehydrogenase family 3, subfamily A1 | Up | 29 |
| AL3B1 | Aldh3b1 | Aldehyde dehydrogenase 3 family, member B1 | Up | 29 |
| LPIN2 | Lpin2 | Lipin 2 | Up | 25 |
| GRB2 | Grb2 | Growth factor receptor bound protein 2 | Up | 22 |
| PLD1 | Pld1 | Phospholipase D1 | Up | 21 |
| PURA1 | Adssl1 | Adenylosuccinate synthetase like 1 | Up | 20 |
| FLNC | Flnc | Filamin C, gamma | Up | 18 |
| PARVA | Parva | Parvin, alpha | Up | 18 |
| IKBA | Nfkbia | Nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, alpha | Up | 14 |
| DHSO | Sord | Sorbitol dehydrogenase | Up | 14 |
| GSTM4 | Gstm4 | Glutathione S-transferase, mu 4 | Up | 12 |
| AFAD | Mllt4 | Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, drosophila) | Up | 11 |
| PCCA | Pcca | Propionyl-coenzyme a carboxylase, alpha polypeptide | Up | 11 |
| MTM1 | Mtm1 | X-linked myotubular myopathy gene 1 | Up | 9 |
| NDK7 | Nme7 | NME/NM23 family member 7 | Up | 7 |
| NUD16 | Nudt16 | Nudix (nucleoside diphosphate–linked moiety X)-type motif 16 | Up | 7 |
| PGFRA | Pdgfra | Platelet-derived growth factor receptor, alpha polypeptide | Up | 7 |
| LYPA1 | Lypla1 | Lysophospholipase 1 | Up | 6 |
| TPM4 | Tpm4 | Tropomyosin 4 | Up | 6 |
| KC1A | Csnk1a1 | Casein kinase 1, alpha 1 | Up | 5 |
| PCAT1 | Lpcat1 | Lysophosphatidylcholine acyltransferase 1 | Up | 5 |
| GP1BA | Gp1ba | Glycoprotein 1b, alpha polypeptide | Up | 4 |
| MRC1 | Mrc1 | Mannose receptor, C type 1 | Up | 4 |
| NAGAB | Naga | N-acetyl galactosaminidase, alpha | Up | 4 |
| MUTA | Mut | Methylmalonyl-coenzyme a mutase | Up | 3 |
| PI4KA | Pi4ka | Phosphatidylinositol 4-kinase, catalytic, alpha polypeptide | Up | 2 |
| ECHA | Hadha | Hydroxyacyl-coenzyme a dehydrogenase/3-ketoacyl-coenzyme a thiolase/enoyl-coenzyme a hydratase (trifunctional protein), alpha subunit | Down | 27 |
| ECHB | Hadhb | Hydroxyacyl-coenzyme a dehydrogenase/3-ketoacyl-coenzyme a thiolase/enoyl-coenzyme a hydratase (trifunctional protein), beta subunit | Down | 21 |
| PURA2 | Adss | Adenylosuccinate synthetase, non-muscle | Down | 20 |
| MGST3 | Mgst3 | Microsomal glutathione S-transferase 3 | Down | 12 |
| UMPS | Umps | Uridine monophosphate synthetase | Down | 9 |
| HCFC1 | Hcfc1 | Host cell factor C1 | Down | 5 |
| FIP1 | Fip1l1 | FIP1-like 1 ( | Down | 4 |
| PML | Pml | Promyelocytic leukemia | Down | 4 |
| GDIR2 | Arhgdib | Rho, GDP dissociation inhibitor (GDI) beta | Down | 2 |
| CATs | Ctss | Cathepsin S | Down | 2 |
| SRSF5 | Srsf5 | Serine/arginine-rich splicing factor 5 | Down | 2 |
| SRSF7 | Srsf7 | Serine/arginine-rich splicing factor 7 | Down | 2 |
| TXD12 | Txndc12 | Thioredoxin domain containing 12 (endoplasmic reticulum) | Down | 2 |
FIGURE 5The key regulatory genes between the T + SF group and the GL-pp group and the function enrichment analysis. (A) Heat map of 43 key regulatory genes between the T + SF group and the GL-pp group with the gene names listed on the right (orange indicates a higher expression level, and blue indicates a lower expression level). (B) The significantly upregulated GO biological process clusters with upregulated different genes. (C) The significantly upregulated KEGG pathway clusters with upregulated different genes. (D) Significantly downregulated GO biological process and KEGG pathway clusters with downregulated difference genes. (E) Significantly altered GO biological process and KEGG pathway clusters among all 43 key regulatory genes. (F) The network plot of significantly upregulated pathways was visualized with Cytoscape software. (G) The combination of significantly altered pathways was visualized with Cytoscape software. Each node represented an enriched term, and nodes were colored by clusters, that is, the same color in the network means the same; for example, red represents focal adhesion.
Terms of the KEGG signal pathway and GO biology function in “focal adhesion” and “response to hormone” clusters based on the analysis of the global signal transduction network.
| cluster | Terms | Description | lgP | Genes |
|---|---|---|---|---|
|
| mmu04510 | Focal adhesion | −7.87302 | Ptk2, Grb2, |
| mmu05231 | Choline metabolism in cancer | −4.87407 | Grb2, pdgfra, Lypla1, Pld1 | |
| mmu04151 | PI3K–Akt signaling pathway | −3.84789 | Ptk2, Grb2, | |
| mmu04014 | Ras signaling pathway | −3.46729 | Grb2, afdn, pdgfra, Pld1 | |
| mmu04072 | Phospholipase D signaling pathway | −2.87998 | Grb2, pdgfra, Pld1 | |
| mmu05205 | Proteoglycans in cancer | −2.46327 | Ptk2, Grb2, flnc | |
| GO:0061138 | Morphogenesis of a branching epithelium | −2.356 | Grb2, pdgfra, Yap1 | |
| GO:0030029 | Actin filament-based process | −2.28504 | Grb2, pdgfra, parva, flnc, Tpm4 | |
| GO:0001763 | Morphogenesis of a branching structure | −2.2483 | Grb2, pdgfra, Yap1 | |
| mmu04010 | MAPK signaling pathway | −2.21937 | Grb2, pdgfra, flnc | |
|
| GO:0009725 | Response to hormone | −4.15411 | Aldh3a1, Ptk2, Grb2, Pld1, sord, Yap1, Lpin2 |
| mmu05222 | Small cell lung cancer | −3.60391 | Ptk2, | |
| mmu05200 | Pathways in cancer | −3.5909 | Ptk2, Grb2, | |
| GO:1901652 | Response to peptide | −3.57565 | Ptk2, Grb2, nfkbia, Pld1, Lpin2 | |
| mmu05215 | Prostate cancer | −3.54359 | Grb2, nfkbia, pdgfra | |
| GO:0043434 | Response to peptide hormone | −2.85245 | Ptk2, Grb2, Pld1, Lpin2 | |
| mmu04062 | Chemokine signaling pathway | −2.54939 | Ptk2, Grb2, nfkbia | |
| GO:0071375 | Cellular response to peptide hormone stimulus | −2.23374 | Ptk2, Grb2, Lpin2 | |
| GO:0032870 | Cellular response to hormone stimulus | −2.11301 | Ptk2, Grb2, Yap1, Lpin2 | |
| GO:1901653 | Cellular response to peptide | −2.03188 | Ptk2, Grb2, Lpin2 | |
| GO:0071417 | Cellular response to organonitrogen compound | −2.00286 | Ptk2, Grb2, pdgfra, Lpin2 |
FIGURE 6Effect of GL-pp on species number and relative abundance of the gut microbiota in mice with B16-F10-luc-G5 and SF. (A) The Venn diagram of OTUs in CON, Tumor, T + SF, and GL-pp groups. (B) Relative abundance of the gut microbiota in the four groups at the phylum level. (C) The rarefaction curves. (D) The relative abundance curves. (E) The heat map of top 35 genera of gut microbiota in the four groups with the phylum on the left side (different phyla are shown in different colors).
FIGURE 7Effect of GL-pp on the diversity and the significantly altered taxa of gut microbiota in mice with B16-F10-luc-G5 and SF. The α-diversity analysis including observed species (A), Shannon Index (B), Chao1 Index (C), ACE Index (D), and Simpson Index (E) is shown. The NMDS analysis results are shown in (F). The relative abundance of significantly altered taxa, including genus Bacteroides (G), genus Parvibacter (H), family Christensenellaceae (I), genus Desulfovibrio (J), and genus Odoribacter (K) in the Tumor, T + SF, and GL-pp groups are shown in (G–K). n = 3. Results are shown as mean ± SD. # p < 0.05 compared with the Tumor group; △ p < 0.05 compared with the T + SF group.
FIGURE 8Effect of GL-pp on TAM polarization and TNF-α serum level in mice with B16-F10-luc-G5 and SF. (A) The flow cytometry results with CD86 and CD206 label to show TAM polarization. The type of tumor-related macrophages in pulmonary metastasis tumor tissue was detected with CD86 for type M1 macrophage and CD206 for type M2 macrophage. (B) The statistical results of M1/M2 ratio. (C) The TNF-α serum level in mice detected by ELISA. n = 5. The results are shown as mean ± SD. **p <0.01 compared with the CON group; ## p < 0.01 compared with the Tumor group; △△ p < 0.01 compared with the T + SF group.